Italia markets closed

    +116,97 (+0,48%)
  • Dow Jones

    +161,90 (+0,47%)
  • Nasdaq

    +134,52 (+0,99%)
  • Nikkei 225

    +26,45 (+0,09%)
  • Petrolio

    +0,25 (+0,39%)

    +923,37 (+1,96%)
  • CMC Crypto 200

    +73,12 (+5,09%)
  • Oro

    +17,60 (+0,97%)

    +0,0092 (+0,77%)
  • S&P 500

    +27,84 (+0,66%)

    -26,81 (-0,09%)
  • Euro Stoxx 50

    +34,81 (+0,87%)

    +0,0006 (+0,07%)

    +0,0013 (+0,12%)

    +0,0106 (+0,72%)

Investors Who Bought Geratherm Medical (ETR:GME) Shares Three Years Ago Are Now Down 22%

Simply Wall St
·3 minuto per la lettura

Many investors define successful investing as beating the market average over the long term. But its virtually certain that sometimes you will buy stocks that fall short of the market average returns. Unfortunately, that's been the case for longer term Geratherm Medical AG (ETR:GME) shareholders, since the share price is down 22% in the last three years, falling well short of the market decline of around 8.6%. Unfortunately the share price momentum is still quite negative, with prices down 12% in thirty days. This could be related to the recent financial results - you can catch up on the most recent data by reading our company report.

View our latest analysis for Geratherm Medical

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

Geratherm Medical saw its EPS decline at a compound rate of 38% per year, over the last three years. This fall in the EPS is worse than the 8.0% compound annual share price fall. So the market may not be too worried about the EPS figure, at the moment -- or it may have previously priced some of the drop in. With a P/E ratio of 92.54, it's fair to say the market sees a brighter future for the business.

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).

XTRA:GME Past and Future Earnings May 23rd 2020
XTRA:GME Past and Future Earnings May 23rd 2020

Dive deeper into Geratherm Medical's key metrics by checking this interactive graph of Geratherm Medical's earnings, revenue and cash flow.

What About Dividends?

It is important to consider the total shareholder return, as well as the share price return, for any given stock. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. In the case of Geratherm Medical, it has a TSR of -12% for the last 3 years. That exceeds its share price return that we previously mentioned. This is largely a result of its dividend payments!

A Different Perspective

It's nice to see that Geratherm Medical shareholders have received a total shareholder return of 10% over the last year. Of course, that includes the dividend. There's no doubt those recent returns are much better than the TSR loss of 1.0% per year over five years. This makes us a little wary, but the business might have turned around its fortunes. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Take risks, for example - Geratherm Medical has 6 warning signs (and 1 which is concerning) we think you should know about.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on DE exchanges.

Love or hate this article? Concerned about the content? Get in touch with us directly. Alternatively, email

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Thank you for reading.